H.C. Wainwright Reaffirms Their Buy Rating on Bio-Path Holdings (BPTH)

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Bio-Path Holdings (BPTHResearch Report) today and set a price target of $9.00. The company’s shares opened today at $1.57.

Chen covers the Healthcare sector, focusing on stocks such as Veru, Applied DNA Sciences, and Aslan Pharmaceuticals. According to TipRanks, Chen has an average return of -28.1% and a 24.40% success rate on recommended stocks.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bio-Path Holdings with a $9.00 average price target.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $5.28 and a one-year low of $1.29. Currently, Bio-Path Holdings has an average volume of 47.7K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Bio-Path Holdings, Inc. is a biotechnology company, which engages in the develpment of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline include Prexigebersen, BP1002, and BP1003. The company was founded by Peter Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX.

Read More on BPTH:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More